Lacosamide vs Levetiracetam — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Anticonvulsant

Lacosamide

Brand: MOTPOLY XR

First FDA approval: 2009-05-26

Anticonvulsant

Levetiracetam

Brand: Keppra

First FDA approval: 2000-04-24

Lowest NADACAcquisition cost floor across all NDCs

$0.095Per unit

$0.030Per unit

Average NADACAcross all dosage forms and strengths

$2.54Up to $21.31

$0.917Up to $19.90

Generic manufacturersActive ANDA holders — FDA Orange Book

2871 total ANDAs filed

52138 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$252.2MFull year

$384.3MFull year

Part D claims (CY24)Total fills, all strengths

1.4M243K beneficiaries

7.4M1.6M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$174Per claim, all NDCs

$52Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

12Minimal friction

102Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

7Limited friction

159Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes28 manufacturers

Yes52 manufacturers